ChoA Pharmaceutical Co.Ltd - Asset Resilience Ratio
ChoA Pharmaceutical Co.Ltd (034940) has an Asset Resilience Ratio of 0.32% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ChoA Pharmaceutical Co.Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2025)
This chart shows how ChoA Pharmaceutical Co.Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ChoA Pharmaceutical Co.Ltd (034940) total assets.
Liquid Assets Composition Over Time
This chart breaks down ChoA Pharmaceutical Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ChoA Pharmaceutical Co.Ltd (034940) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩199.74 Million | 0.32% |
| Total Liquid Assets | ₩199.74 Million | 0.32% |
Asset Resilience Insights
- Limited Liquidity: ChoA Pharmaceutical Co.Ltd maintains only 0.32% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ChoA Pharmaceutical Co.Ltd Industry Peers by Asset Resilience Ratio
Compare ChoA Pharmaceutical Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for ChoA Pharmaceutical Co.Ltd (2001–2025)
The table below shows the annual Asset Resilience Ratio data for ChoA Pharmaceutical Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.31% | ₩198.12 Million ≈ $134.26K |
₩64.68 Billion ≈ $43.83 Million |
-7.36pp |
| 2024-12-31 | 7.67% | ₩5.47 Billion ≈ $3.71 Million |
₩71.32 Billion ≈ $48.33 Million |
+1.84pp |
| 2023-12-31 | 5.83% | ₩4.33 Billion ≈ $2.93 Million |
₩74.22 Billion ≈ $50.30 Million |
-2.30pp |
| 2022-12-31 | 8.14% | ₩6.97 Billion ≈ $4.72 Million |
₩85.64 Billion ≈ $58.04 Million |
-4.53pp |
| 2021-12-31 | 12.66% | ₩10.19 Billion ≈ $6.91 Million |
₩80.51 Billion ≈ $54.56 Million |
+1.67pp |
| 2020-12-31 | 10.99% | ₩9.06 Billion ≈ $6.14 Million |
₩82.38 Billion ≈ $55.83 Million |
-5.71pp |
| 2019-12-31 | 16.70% | ₩14.49 Billion ≈ $9.82 Million |
₩86.74 Billion ≈ $58.78 Million |
+2.50pp |
| 2018-12-31 | 14.20% | ₩11.94 Billion ≈ $8.09 Million |
₩84.04 Billion ≈ $56.95 Million |
-0.40pp |
| 2017-12-31 | 14.60% | ₩12.20 Billion ≈ $8.27 Million |
₩83.52 Billion ≈ $56.60 Million |
+6.94pp |
| 2016-12-31 | 7.66% | ₩5.75 Billion ≈ $3.90 Million |
₩75.10 Billion ≈ $50.89 Million |
+4.18pp |
| 2015-12-31 | 3.48% | ₩2.59 Billion ≈ $1.75 Million |
₩74.35 Billion ≈ $50.38 Million |
-8.35pp |
| 2014-12-31 | 11.83% | ₩8.76 Billion ≈ $5.94 Million |
₩74.05 Billion ≈ $50.18 Million |
+1.96pp |
| 2013-12-31 | 9.87% | ₩6.99 Billion ≈ $4.73 Million |
₩70.82 Billion ≈ $47.99 Million |
-24.07pp |
| 2005-12-31 | 33.93% | ₩18.22 Billion ≈ $12.35 Million |
₩53.70 Billion ≈ $36.39 Million |
+28.22pp |
| 2004-12-31 | 5.71% | ₩2.16 Billion ≈ $1.46 Million |
₩37.72 Billion ≈ $25.56 Million |
-14.42pp |
| 2003-12-31 | 20.13% | ₩9.94 Billion ≈ $6.74 Million |
₩49.39 Billion ≈ $33.47 Million |
+2.88pp |
| 2002-12-31 | 17.25% | ₩10.46 Billion ≈ $7.09 Million |
₩60.60 Billion ≈ $41.07 Million |
-0.18pp |
| 2001-12-31 | 17.43% | ₩12.82 Billion ≈ $8.69 Million |
₩73.54 Billion ≈ $49.83 Million |
-- |
About ChoA Pharmaceutical Co.Ltd
ChoA Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea. The company produces approximately 200 medicines and health foods, including 30 internal ampoule products, such as Hepos, Fematin, Vasoclean, Mabis, etc. Its products include drugs for digestive, circulatory, and respiratory systems; vitamins, minerals, and nutrients; anti inflammation and analgesics; peripheral ne… Read more